<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Polymers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Polymers (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">3589</journal-id><journal-id journal-id-type="pmc-domain">polymers</journal-id><journal-id journal-id-type="publisher-id">polymers</journal-id><journal-title-group><journal-title>Polymers</journal-title></journal-title-group><issn pub-type="epub">2073-4360</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11207985</article-id><article-id pub-id-type="pmcid-ver">PMC11207985.1</article-id><article-id pub-id-type="pmcaid">11207985</article-id><article-id pub-id-type="pmcaiid">11207985</article-id><article-id pub-id-type="pmid">38932015</article-id><article-id pub-id-type="doi">10.3390/polym16121667</article-id><article-id pub-id-type="publisher-id">polymers-16-01667</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>In Vitro and In Vivo Drug Release from a Nano-Hydroxyapatite Reinforced Resorbable Nanofibrous Scaffold for Treating Female Pelvic Organ Prolapse</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4231-3502</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="YP">Yi-Pin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-polymers-16-01667" ref-type="aff">1</xref><xref rid="af2-polymers-16-01667" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lo</surname><given-names initials="TS">Tsia-Shu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="af3-polymers-16-01667" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chien</surname><given-names initials="YH">Yu-Han</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af4-polymers-16-01667" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuo</surname><given-names initials="YH">Yi-Hua</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af4-polymers-16-01667" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2083-4865</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="SJ">Shih-Jung</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-polymers-16-01667" ref-type="aff">4</xref><xref rid="af5-polymers-16-01667" ref-type="aff">5</xref><xref rid="c1-polymers-16-01667" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Hu</surname><given-names initials="X">Xiao</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-polymers-16-01667"><label>1</label>Department of Obstetrics and Gynecology, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan; <email>8805037@cgmh.org.tw</email></aff><aff id="af2-polymers-16-01667"><label>2</label>School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan</aff><aff id="af3-polymers-16-01667"><label>3</label>Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan 33305, Taiwan; <email>2378@cgmh.org.tw</email></aff><aff id="af4-polymers-16-01667"><label>4</label>Department of Mechanical Engineering, Chang Gung University, Taoyuan 33302, Taiwan; <email>luhan871202@gmail.com</email> (Y.-H.C.); <email>shelly871117@gmail.com</email> (Y.-H.K.)</aff><aff id="af5-polymers-16-01667"><label>5</label>Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan 33305, Taiwan</aff><author-notes><corresp id="c1-polymers-16-01667"><label>*</label>Correspondence: <email>shihjung@mail.cgu.edu.tw</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">465537</issue-id><elocation-id>1667</elocation-id><history><date date-type="received"><day>07</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>05</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-28 09:25:31.717"><day>28</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="polymers-16-01667.pdf"/><abstract><p>Pelvic prolapse stands as a substantial medical concern, notably impacting a significant segment of the population, predominantly women. This condition, characterized by the descent of pelvic organs, such as the uterus, bladder, or rectum, from their normal positions, can lead to a range of distressing symptoms, including pelvic pressure, urinary incontinence, and discomfort during intercourse. Clinical challenges abound in the treatment landscape of pelvic prolapse, stemming from its multifactorial etiology and the diverse array of symptoms experienced by affected individuals. Current treatment options, while offering relief to some extent, often fall short in addressing the full spectrum of symptoms and may pose risks of complications or recurrence. Consequently, there exists a palpable need for innovative solutions that can provide more effective, durable, and patient-tailored interventions for pelvic prolapse. We manufactured an integrated polycaprolactone (PCL) mesh, reinforced with nano-hydroxyapatite (nHA), along with drug-eluting poly(lactic-co-glycolic acid) (PLGA) nanofibers for a prolapse scaffold. This aims to offer a promising avenue for enhanced treatment outcomes and improved quality of life for individuals grappling with pelvic prolapse. Solution extrusion additive manufacturing and electrospinning methods were utilized to prepare the nHA filled PCL mesh and drug-incorporated PLGA nanofibers, respectively. The pharmaceuticals employed included metronidazole, ketorolac, bleomycin, and estrone. Properties of fabricated resorbable scaffolds were assessed. The in vitro release characteristics of various pharmaceuticals from the meshes/nanofibers were evaluated. Furthermore, the in vivo drug elution pattern was also estimated on a rat model. The empirical data show that nHA reinforced PCL mesh exhibited superior mechanical strength to virgin PCL mesh. Electrospun resorbable nanofibers possessed diameters ranging from 85 to 540 nm, and released effective metronidazole, ketorolac, bleomycin, and estradiol, respectively, for 9, 30, 3, and over 30 days in vitro. Further, the mesh/nanofiber scaffolds also liberated high drug levels at the target site for more than 28 days in vivo, while the drug concentrations in blood remained low. This discovery suggests that resorbable scaffold can serve as a viable option for treating female pelvic organ prolapse.</p></abstract><kwd-group><kwd>resorbable meshes</kwd><kwd>drug-embedded nanofibers</kwd><kwd>sustained release</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Science and Technology, Taiwan</funding-source><award-id>111-2221-E-182-004-MY3</award-id></award-group><award-group><funding-source>Chang Gung Memorial Hospital</funding-source><award-id>CMRPD2M0132</award-id><award-id>CMRPG2L0071</award-id></award-group><funding-statement>The financial supports of the Ministry of Science and Technology, Taiwan (Contract No. 111-2221-E-182-004-MY3) and Chang Gung Memorial Hospital (Contract No. CMRPD2M0132 and CMRPG2L0071) for this research are gratefully acknowledged.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-polymers-16-01667"><title>1. Introduction</title><p>Fecal pelvic organ prolapse (FPOP) stands as a pressing medical issue with profound social and economic ramifications, affecting a substantial portion of the population worldwide. Statistical data reveal a significant increase in the prevalence of FPOP cases over recent years, underscoring the urgency of effective interventions. Patients grappling with FPOP endure a myriad of challenges, ranging from physical discomfort to psychological distress, highlighting the critical need for innovative solutions [<xref rid="B1-polymers-16-01667" ref-type="bibr">1</xref>,<xref rid="B2-polymers-16-01667" ref-type="bibr">2</xref>,<xref rid="B3-polymers-16-01667" ref-type="bibr">3</xref>]. Current approaches primarily involve surgical intervention combined with the grafting of artificial mesh. Non-degradable synthesis meshes composed of polypropylene (PP) have found extensive application in fortifying the pelvic floor for patients experiencing recurrent pelvic organ prolapse following native tissue repair surgery [<xref rid="B4-polymers-16-01667" ref-type="bibr">4</xref>]. Nevertheless, the implantation of these meshes can lead to complications like mesh erosion, potentially causing issues such as tissue infections, with an occurrence frequency ranging from 7% to 25% [<xref rid="B4-polymers-16-01667" ref-type="bibr">4</xref>]. This necessitates additional surgical procedures to eradicate the non-degradable meshes [<xref rid="B5-polymers-16-01667" ref-type="bibr">5</xref>,<xref rid="B6-polymers-16-01667" ref-type="bibr">6</xref>].</p><p>An optimal scaffold for therapy of FPOP should meet the following criteria: (1) possess sufficient force to maintain the pelvic floor; (2) exhibit excellent flexibility to facilitate implantation and fixation; (3) deliver precise drug or hormone levels to the intended location to achieve pain relief, infection management, and preservation of reproductive tissues, as well as stimulate the development of connective tissues to strengthen the pelvic floor; (4) degrade after completing its function and be biocompatible, ensuring that the material biodegradation process does not cause any tissue irritation [<xref rid="B7-polymers-16-01667" ref-type="bibr">7</xref>,<xref rid="B8-polymers-16-01667" ref-type="bibr">8</xref>].</p><p>Ongoing research endeavors aim to address these deficiencies, focusing on material innovations and treatment modalities to enhance patient outcomes [<xref rid="B9-polymers-16-01667" ref-type="bibr">9</xref>,<xref rid="B10-polymers-16-01667" ref-type="bibr">10</xref>,<xref rid="B11-polymers-16-01667" ref-type="bibr">11</xref>]. Rynkevic et al. [<xref rid="B8-polymers-16-01667" ref-type="bibr">8</xref>] investigated the potential use of electrospun nanofibers made from 2-ureido-[1H]-pyrimidin-4-one (UPy)-modified polycaprolactone (PCL) for prolapse repair. Their findings revealed that UPy-PCL nanofibrous meshes exhibited no significant weight loss or thinning during in vitro degradation. However, these meshes experienced plastic deformation and a notable change in elongation after degradation in an acidic medium. Dominguez-Robles et al. [<xref rid="B12-polymers-16-01667" ref-type="bibr">12</xref>] developed drug-loaded thermoplastic polyurethane (TPU) meshes using fused deposition modeling additive manufacturing. They demonstrated that incorporating levofloxacin into the TPU matrix allows for the preparation of anti-infective vaginal meshes with enhanced mechanical properties compared to current PP vaginal meshes. Nevertheless, the non-degradable nature of TPU may pose a challenge in the long term. The pursuit of an optimal material for FPOP is hampered by the failure of current options to meet essential criteria, such as biocompatibility, mechanical strength, and long-term efficacy, thus delineating critical gaps in the field [<xref rid="B5-polymers-16-01667" ref-type="bibr">5</xref>,<xref rid="B6-polymers-16-01667" ref-type="bibr">6</xref>].</p><p>Additionally, the incorporation of therapeutic agents, such as antibiotics or anti-inflammatory drugs, within the scaffold enables targeted treatment, addressing underlying inflammation and infection, common occurrences in FPOP cases. Furthermore, the ability of the scaffold to biodegrade over time aligns with the natural healing process of the body, minimizing the risk of long-term complications associated with permanent implants. Current state-of-the-art approaches often rely on non-degradable materials or lack the capability for controlled drug release, presenting significant limitations in achieving optimal treatment outcomes. The innovation of the proposed material lies in its ability to address these critical needs simultaneously, offering a multifaceted solution that enhances therapeutic efficacy while minimizing adverse effects, thereby heralding a new era in FPOP management.</p><p>We exploited a nano-hydroxyapatite (nHA) reinforced resorbable nanofibrous scaffold for therapy of FPOP. nHA filled polycaprolactone (PCL) mesh was manufactured utilizing a solution-extrusion additive manufacturing device [<xref rid="B13-polymers-16-01667" ref-type="bibr">13</xref>]. PCL has garnered significant attention as an implantable biomaterial due to its degradation through ester linkages hydrolysis in physiological conditions, such as those found within the human body [<xref rid="B14-polymers-16-01667" ref-type="bibr">14</xref>]. The nHA filler, a biocompatible material renowned for its osteoconductive properties, serves as a reinforcing agent, augmenting the mechanical strength and structural integrity of the scaffold. Its integration within the material structure, strategically dispersed throughout the polymer matrix, imparts enhanced stability and biocompatibility to the final construct.</p><p>Metronidazole-, ketorolac-, bleomycin-, and estrone-embedded poly(lactic-co-glycolic acid) (PLGA) nanofibrous mats were manufactured utilizing an electrospinner [<xref rid="B15-polymers-16-01667" ref-type="bibr">15</xref>,<xref rid="B16-polymers-16-01667" ref-type="bibr">16</xref>,<xref rid="B17-polymers-16-01667" ref-type="bibr">17</xref>]. PLGA stands as one of the extensively documented polymers utilized in the formulation of safe and efficient vaccine, drug, and gene delivery systems. The polymer also offers advantages over natural polymers like collagen, gelatin, or chitosan, which have drawbacks such as batch-to-batch variability, immunogenicity, and limited mechanical strength [<xref rid="B18-polymers-16-01667" ref-type="bibr">18</xref>]. Metronidazole, an antibiotic, is extensively utilized in various medical conditions, including trichomoniasis, amebiasis, giardiasis, etc. [<xref rid="B19-polymers-16-01667" ref-type="bibr">19</xref>], and has found various applications in obstetrics and gynecology [<xref rid="B20-polymers-16-01667" ref-type="bibr">20</xref>]. Ketorolac has been one of the nonsteroidal anti-inflammatory drugs (NSAID) widely employed to address moderate to severe pain [<xref rid="B21-polymers-16-01667" ref-type="bibr">21</xref>]. Bleomycin is a medication adopted to treat lung cancer, which can lead to pulmonary fibrosis, occurring upon increasing the dosage. This medication has also been reported to induce dermal fibrosis [<xref rid="B22-polymers-16-01667" ref-type="bibr">22</xref>,<xref rid="B23-polymers-16-01667" ref-type="bibr">23</xref>]. Estrone, an estrogen steroid hormone, serves as the principal hormone associated with the female reproductive system [<xref rid="B24-polymers-16-01667" ref-type="bibr">24</xref>]. After fabrication, the mechanical properties of nHA reinforced mesh and drug loaded nanofibers were determined by a tensile tester. The morphology of the nanofibers was also observed using scanning electron microscopy (SEM). The in vitro discharge profiles of pharmaceuticals from the nanofibers were assessed using an elution scheme and high-performance liquid chromatography (HPLC). In addition, the in vivo elution behavior was estimated on a rat model.</p><p>In this context, the proposed innovation of a novel material emerges as a beacon of hope, poised to rectify the shortcomings of existing approaches. This groundbreaking material offers a paradigm shift in FPOP management, boasting unique features and advantages that promise to revolutionize treatment paradigms.</p></sec><sec id="sec2-polymers-16-01667"><title>2. Materials and Method</title><sec id="sec2dot1-polymers-16-01667"><title>2.1. Additive Manufacturing of Resorbable Mesh</title><p>PCL (molecular weight (MW): 80 kDa) and dichloromethane (DCM) were adopted, both obtained from Sigma-Aldrich (Saint Louis, MO, USA). nHA with a size of less than 200 nm (molecular weight of 502.31 g/mol, Sigma-Aldrich) was employed as the filler. Following the design of commercially available PP mesh, biodegradable PCL mesh was fabricated employing a lab-scale solution-extrusion additive manufacturing device (<xref rid="polymers-16-01667-f001" ref-type="fig">Figure 1</xref>A) [<xref rid="B13-polymers-16-01667" ref-type="bibr">13</xref>], which comprises an extrusion feeder, steering step motors, a syringe along with a delivering nozzle (inner diameter: 180 &#956;m), a collection table, and a control port connected to a computer. PCL (2500 mg) and nHA (125 mg) were first stir mixed with DCM of 6 mL. The solution was subsequently loaded into the syringe/dispensing nozzle of the additive manufacturing device. During the additive manufacturing process, the syringe/nozzle was actuated through a computer-monitored motor. The fill density, print speed, and print orientation were set to 50%, 40 mm/s, and 60&#176;, respectively. Once the DCM evaporates, PCL/nHA strips, approximately 0.2 mm thick, were laid on the table in successive layers. The PCL/nHA mixture was deposited on the gathering table layer-by-layer. PCL mesh, having a pore diameter of 3 mm and a thickness of 0.5 mm, was acquired on the table (<xref rid="polymers-16-01667-f001" ref-type="fig">Figure 1</xref>B). Meanwhile, meshes of virgin PCL were also prepared by dissolving PCL of 2.5 g in DCM of 6 mL, for comparison purpose [<xref rid="B25-polymers-16-01667" ref-type="bibr">25</xref>,<xref rid="B26-polymers-16-01667" ref-type="bibr">26</xref>].</p></sec><sec id="sec2dot2-polymers-16-01667"><title>2.2. Drug-Embedded Nanofibers</title><p>PLGA (LA:GA of 50:50, MW: 33 kDa, Sigma-Aldrich) hexafluoroisopropanol (HFIP, Sigma-Aldrich) were adopted [<xref rid="B27-polymers-16-01667" ref-type="bibr">27</xref>,<xref rid="B28-polymers-16-01667" ref-type="bibr">28</xref>]. Bi-layered drug-embedded nanofibers were prepared. Based on the experiences gained from our previous work on the electrospinning of PLGA nanofibers under appropriate conditions [<xref rid="B29-polymers-16-01667" ref-type="bibr">29</xref>], PLGA (896 mg), metronidazole (112 mg), and ketorolac (112 mg) were initially stirred and blended with HFIP (4 mL), and then spun using electrospinning equipment. The rate of delivery for the solution was set at 0.7 mL/h. The voltage used was 17 kV and the travel distance from the nozzle to the gathering plate was 14 cm. To prepare the second layer, PLGA (896 mg), bleomycin (112 mg), and estrone (112 mg) were dissolved in HFIP (4 mL) and then spun. Bi-layered nanofibrous membranes were consequently produced, with a thickness of 0.21 mm (each layer measuring around 0.105 mm). After spinning, the nanofibers were combined with the printed PCL mesh (<xref rid="polymers-16-01667-f001" ref-type="fig">Figure 1</xref>C) into a single drug-eluting scaffold. The prepared scaffolds were placed in a chamber maintained at 40 &#176;C for 72 h to evaporate the solvents.</p></sec><sec id="sec2dot3-polymers-16-01667"><title>2.3. Tensile Property</title><p>The tensile property of additively manufactured virgin PCL and nHA filled PCL meshes was assessed by a tensile testing device (Lloyd, Ametek, Berwyn, PA, USA). Specimens (2 cm &#215; 5 cm) were cut from the meshes for the tests. The extensional rate was set at 100 mm/min and the ultimate load and deformation were recorded [<xref rid="B30-polymers-16-01667" ref-type="bibr">30</xref>]. The tests were conducted at 25 &#176;C, with a humidity of 60%, and three analyses were conducted (N = 3) to ensure the accuracy and reliability of the results.</p><p>Additionally, the tensile characteristic of pristine nanofibers and drug-embedded nanofibers was also evaluated. Samples of 2 cm &#215; 5 cm were sliced from the nanofibrous membranes and measured by the Lloyd equipment (N = 3). The stretching rate was 100 mm/min [<xref rid="B27-polymers-16-01667" ref-type="bibr">27</xref>,<xref rid="B28-polymers-16-01667" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot4-polymers-16-01667"><title>2.4. Scanning Electron Microscope (SEM) Observation</title><p>The microscopic structure of printed mesh and spun nanofibers was appraised by utilizing SEM after they were coated with gold. The dimensional distribution of electrospun fibers was determined by analyzing 100 randomly selected fibers (N = 3) using a commercial ImageJ (version 1.49) code provided by the National Institutes of Health, Bethesda, MD, USA.</p></sec><sec id="sec2dot5-polymers-16-01667"><title>2.5. Wetting Angle</title><p>To assess hydrophilicity, wetting angle of pristine PLGA and drug-embedded PLGA nanofibrous membranes was measured. Distilled water was gently deposited on the nanofiber surface (1 cm &#215; 1 cm) and analyzed employing a video monitor. The measurement was conducted in triplicate (N = 3).</p></sec><sec id="sec2dot6-polymers-16-01667"><title>2.6. Fourier Transform Infrared Spectroscopy (FTIR)</title><p>Fourier transform infrared spectroscopy (FTIR) analyses were performed to assess the nanofibers&#8217; composition and verify the presence of all introduced pharmaceuticals. To acquire the spectra of the nanofibers charged with the drug, Fourier transform infrared spectroscopy (FTIR) was completed using the Bruker Tensor 27 spectrometer (Billerica, MA, USA). The analysis was conducted at a resolution of 4 cm<sup>&#8722;1</sup> in the absorption mode, with a total of 32 scans. The nanofibrous specimen was pressed into KBr discs, with the spectra recorded within the span of 400&#8211;4000 cm<sup>&#8722;1</sup> (N = 3).</p></sec><sec id="sec2dot7-polymers-16-01667"><title>2.7. Differential Scanning Calorimetry Assessment</title><p>Scanning calorimetry (DSC) assays were conducted to evaluate the composition of the nanofibers and confirm the inclusion of added pharmaceuticals. The thermal characteristics of pristine PLGA nanofibers and drug-embedded PLGA nanofibers were examined through DSC using TA Instruments equipment located in New Castle, DE, USA. The polymeric specimens underwent scanning from 30 &#176;C to 300 &#176;C, with a constant heating speed of 10 &#176;C/min (N = 3).</p></sec><sec id="sec2dot8-polymers-16-01667"><title>2.8. In Vitro Drug Release</title><p>The discharge characteristic of metronidazole, ketorolac, bleomycin, and estrone from the drug-embedded nanofibrous membranes was investigated. The nanofibrous sample (approximately 1 cm &#215; 1.5 cm) was filled into a glass tube containing phosphate-buffered saline (PBS) of 1 mL (N = 3). The tube was then placed in an isothermal chamber at 37 &#176;C for 24 h, before the solution was gathered and analyzed. New PBS of 1 mL was added to the tube for the subsequent 24 h interval, and this procedure was repeated for a total of 30 days.</p><p>The pharmaceutical concentrations in the gathered solutions were determined utilizing HPLC, conducted on a Hitachi L-2200R multi-solvent delivery system based in Tokyo, Japan. For metronidazole [<xref rid="B31-polymers-16-01667" ref-type="bibr">31</xref>], the mobile phase consisted of acetonitrile:PBS in a ratio of 30:70 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) at pH 7.0. The assay parameters included a wavelength of 319 nm and a flow rate of 1.0 mL/min. An Inertsil C18 column (250 &#215; 4.6 mm &#215; 5 mm) from Supelco (Sigma-Aldrich) was employed, with a retention time ranging from 3.5 to 4.3 min. To assay ketorolac, an Ascentic C18 (250 &#215; 4.6 mm &#215; 5 mm) column (Supelco, Sigma-Aldrich) was employed. The mobile phase included acetonitrile and 5 mM ammonium acetate (pH 3.5) in a ratio of 60:40 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) [<xref rid="B32-polymers-16-01667" ref-type="bibr">32</xref>]. Absorbance was measured at a wavelength of 306 nm, with a flow rate of 1.0 mL/min. The retention time was set at 2.5 min.</p><p>Additionally, the distilled water:acetonitrile:acetic acid (with 0.0085 M sodium heptanesulfonate) at a ratio of 70:25:5 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) was adopted as the mobile phase for bleomycin [<xref rid="B33-polymers-16-01667" ref-type="bibr">33</xref>]. Absorbance was measured at a wavelength of 295 nm, with a flow rate set at 1.0 mL/min. An Ascentic C18 (150 &#215; 4.6 mm &#215; 5 mm) column (Waters, MA, USA) was adopted for the analysis. The duration of retention was set at 1.6 min. Finally, to evaluate estrone, a Mightysil RP-18 GP 250-4.6 (5 &#181;m) column (Kanto Chemical, Tokyo, Japan) was utilized. The mobile phase contained acetonitrile:PBS (35:65, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) [<xref rid="B34-polymers-16-01667" ref-type="bibr">34</xref>]. Absorbance was measured at a wavelength of 280 nm, with a flow rate set at 1.0 mL/min. The duration of retention was set at 6.8 min. All experiments were completed in triplicate (N = 3).</p></sec><sec id="sec2dot9-polymers-16-01667"><title>2.9. In Vivo Drug Elution</title><p>Sprague-Dawley rats (approximately 300 g) received treatment and care under the supervision of a licensed veterinarian, following the regulations of the National Institute of Health of Taiwan. The entire procedures involving animals acquired approval from the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC: CGMH2018121905). The animals were initially anesthetized with isoflurane. Before implantation, nHA filled PCL meshes and drug-loaded PLGA nanofibers were integrated via sutures (<xref rid="polymers-16-01667-f002" ref-type="fig">Figure 2</xref>A). A 4 cm cut was made in the lower abdomen of each rat (<xref rid="polymers-16-01667-f002" ref-type="fig">Figure 2</xref>B). Following the implantation of resorbable nanofibrous scaffold (3 cm &#215; 1 cm &#215; 5 mm in dimension) (<xref rid="polymers-16-01667-f002" ref-type="fig">Figure 2</xref>C), the wound was sealed using 3-0 Vicryl sutures (Ethicon Inc., Bridgewater, NJ, USA).</p><p>To assess the in vivo release pattern of drug-eluting scaffolds, tissues surrounding the scaffolds were collected on days 1, 3, 7, 14, and 28 (<xref rid="polymers-16-01667-f002" ref-type="fig">Figure 2</xref>D) after implantation using an operational process the same as that employed during the implantation. The pharmaceutical level in the gathered specimens was then determined by HPLC. Additionally, the obtained specimen was stained with hematoxylin and eosin (H&amp;E) and Masson&#8217;s trichrome staining, and examined under a microscope.</p></sec></sec><sec sec-type="results" id="sec3-polymers-16-01667"><title>3. Results</title><sec id="sec3dot1-polymers-16-01667"><title>3.1. Characterization of Drug-Embedded Mesh/Nanofibers</title><p><xref rid="polymers-16-01667-f003" ref-type="fig">Figure 3</xref> displays the tensile test curves of manufactured mesh. The nHA filled PCL meshes exhibited superior strength to that of virgin PCL meshes, demonstrating the capability of nHA in reinforcing the PCL meshes&#8217; function as supporting scaffolds for pelvic floor repair. Additionally, the toughness of nHA filled PCL mesh and virgin PCL was 3.12 J and 0.64 J, respectively. Clearly, the nHA filled mesh exhibited greater toughness than the unfilled mesh. Compared to the unfilled PCL mesh, the nHA-filled mesh exhibited greater deviations among different test trials. This suggests that the dispersion of nHA within the PCL matrix may require optimization during the mixing and printing processes. Enhanced uniformity in nHA distribution is likely necessary to achieve consistent material properties and performance across all trials.</p><p>The mechanical properties of the electrospun nanofibrous membranes were also measured. The experimental results in <xref rid="polymers-16-01667-f004" ref-type="fig">Figure 4</xref> suggest that virgin PLGA nanofibers had greater tensile strength than the drug-loaded nanofibers. Additionally, the virgin nanofibers exhibited greater elongation at breakage compared to the drug-eluting nanofibers. The inclusion of pharmaceuticals in the nanofibers reduces the polymer content, which provides the major resistance to external tensile force. Consequently, the measured mechanical properties decreased accordingly.</p><p><xref rid="polymers-16-01667-f005" ref-type="fig">Figure 5</xref>A shows the SEM image of the printed PCL mesh. With the addition of nHA, some rough surfaces are noted. <xref rid="polymers-16-01667-f005" ref-type="fig">Figure 5</xref>B&#8211;D display the structures of pristine PLGA nanofibers, metronidazole- and ketorolac-incorporated PLGA nanofibers, and bleomycin- and estrone-embedded PLGA nanofibers, respectively. Spun virgin PLGA nanofibers (537.8 &#177; 333.4 nm) exhibited superior size distribution to those of metronidazole/ketorolac/PLGA nanofibers (165.5 &#177; 54.3 nm) and bleomycin/estrone/PLGA nanofibers (84.9 &#177; 33.6 nm). During the electrospinning process, an external electric force is applied to stretch the polymeric mixture. Polymers serve as the primary constituent to oppose the exterior stretching force. In comparison to the pristine nanofibers, the integration of pharmaceuticals resulted in a reduction in the percentage of polymers within the nanofibers. The nanofibers became more susceptible to extension by the external force, resulting in a corresponding decrease in their diameters.</p><p><xref rid="polymers-16-01667-f006" ref-type="fig">Figure 6</xref> shows the measured contact angles of virgin PLGA, metronidazole/ketorolac/PLGA, and bleomycin/estrone/PLGA nanofibers. The measured water contact angle for pristine nanofibers was 118.2 degrees, whereas the contact angles were 78.0 degrees and 54.3 degrees for the metronidazole/ketorolac/PLGA and bleomycin/estrone/PLGA nanofibers, respectively. Despite that pure PLGA nanofibers exhibited hydrophobic characteristics, the inclusion of water-soluble pharmaceuticals significantly increased the hydrophilicity of the electrospun nanofibers.</p><p><xref rid="polymers-16-01667-f007" ref-type="fig">Figure 7</xref> illustrates the FTIR spectra of pristine PLGA nanofibers and drug-embedded PLGA nanofibers. The vibration peak at 702 cm<sup>&#8722;1</sup> was promoted owing to the C&#8211;H bond of incorporated drugs. The fresh peaks at 1593 cm<sup>&#8722;1</sup> and 1530 cm<sup>&#8722;1</sup> were primarily attributed to the C=C bonds of metronidazole [<xref rid="B35-polymers-16-01667" ref-type="bibr">35</xref>] and ketorolac [<xref rid="B36-polymers-16-01667" ref-type="bibr">36</xref>]. Furthermore, the newly observed peak at 1658 cm<sup>&#8722;1</sup> was associated with the C=N bond of bleomycin [<xref rid="B37-polymers-16-01667" ref-type="bibr">37</xref>], and the additional peak at 702 cm<sup>&#8722;1</sup> was intensified by the C&#8211;H bond of incorporated estrone [<xref rid="B38-polymers-16-01667" ref-type="bibr">38</xref>]. Additionally, the peaks at around 1400 cm<sup>&#8722;1</sup> and 3000 cm<sup>&#8722;1</sup>, attributed to OH bonds, were enhanced owing to the inclusion of the pharmaceuticals.</p><p><xref rid="polymers-16-01667-f008" ref-type="fig">Figure 8</xref>A depicts the thermograms of virgin PLGA and metronidazole/ketorolac-embedded PLGA nanofibers. The exothermal peaks at 162.1 &#176;C for metronidazole [<xref rid="B39-polymers-16-01667" ref-type="bibr">39</xref>] and at 163.4 &#176;C and 170.4 &#176;C [<xref rid="B40-polymers-16-01667" ref-type="bibr">40</xref>] for ketorolac diminished after mixing with PLGA. Further, <xref rid="polymers-16-01667-f008" ref-type="fig">Figure 8</xref>B shows the DSC curves for both virgin PLGA and bleomycin and estrone loaded PLGA nanofibers. Again, the exothermal peaks at 98.6 &#176;C for bleomycin [<xref rid="B41-polymers-16-01667" ref-type="bibr">41</xref>] and at 97.8 &#176;C and 143.5 &#176;C [<xref rid="B42-polymers-16-01667" ref-type="bibr">42</xref>] for estrone could not be found after mixing with PLGA.</p><p>All these assays affirmed the successful embedding of pharmaceuticals in the PLGA nanofibers.</p></sec><sec id="sec3dot2-polymers-16-01667"><title>3.2. In Vitro and In Vivo Drug Releases</title><p><xref rid="polymers-16-01667-f009" ref-type="fig">Figure 9</xref> displays the HPLC chromatograms of the pharmaceuticals employed in this work. <xref rid="polymers-16-01667-f010" ref-type="fig">Figure 10</xref> depicts the daily and accumulative discharge profiles of the pharmaceuticals from the nanofibers in vitro. Generally, all pharmaceuticals displayed a tri-phase discharge pattern, i.e., a primary peak at day 1, minor peak releases at various days. This is followed by a consistently and progressively decreasing release. Metronidazole showed the minor peaks at days 7 and 15. Ketorolac displays only one minor peak at day 7, while bleomycin showed minor peaks at 8, 15, 20, and 23 days. Meanwhile, the release of estrone showed tiny bursts at days 7 and 15. Furthermore, the spun nanofibrous membranes consistently released effective metronidazole (above the minimum inhibitory concentration [<xref rid="B43-polymers-16-01667" ref-type="bibr">43</xref>]) for a duration of 9 days, and discharged effective bleomycin and ketorolac (above the minimum therapeutic concentrations [<xref rid="B44-polymers-16-01667" ref-type="bibr">44</xref>,<xref rid="B45-polymers-16-01667" ref-type="bibr">45</xref>]) for 3 and 30 days, respectively. The nanofibrous membrane additionally demonstrated continuous discharge of estrone [<xref rid="B46-polymers-16-01667" ref-type="bibr">46</xref>], spanning a period of more than 30 days.</p><p><xref rid="polymers-16-01667-f011" ref-type="fig">Figure 11</xref> displays the in vivo discharge characteristic of pharmaceuticals from the resorbable nanofibrous scaffolds. The scaffolds discharged high drug concentrations at local tissues for over 28 days. Meanwhile, the pharmaceutical levels in the blood were relatively low at days 1 and 3. <xref rid="polymers-16-01667-f012" ref-type="fig">Figure 12</xref> displays images of H&amp;E staining at various days post-implantation, while <xref rid="polymers-16-01667-f013" ref-type="fig">Figure 13</xref> shows histological images with Masson&#8217;s trichrome staining at different days post-implantation. Fibrosis variations were observed following the implantation of the drug-eluting PCL mesh. Additionally, Masson&#8217;s trichrome staining confirmed a significant increase in collagen fibers.</p></sec></sec><sec sec-type="discussion" id="sec4-polymers-16-01667"><title>4. Discussion</title><p>In our study, we employed additive manufacturing and electrospinning techniques to fabricate resorbable scaffolds embedded with multiple drugs. These scaffolds feature PCL meshes as the backbone to enhance mechanical strength and PLGA nanofibers as the drug delivery vehicle, with the aim of providing therapy for FPOP. PCL is a degradable and compatible synthetic polymer belonging to the class of aliphatic polyester. The polymer&#8217;s unique combination of properties, such as biodegradability, biocompatibility, low melting point, and flexibility and durability, makes it a valuable material in various fields, particularly in drug delivery and tissue engineering [<xref rid="B47-polymers-16-01667" ref-type="bibr">47</xref>]. Our past study on PCL employing cell culture shows that the material exhibited good cell biocompatibility [<xref rid="B48-polymers-16-01667" ref-type="bibr">48</xref>]. Additionally, the slow degradation rate of PCL typically leads to a complete resorption period of 2 to 3 years. The results of our recent work suggest that the maximum tensile strength of PCL did not show an obvious reduction over time after being submerged in a buffered solution for four months [<xref rid="B49-polymers-16-01667" ref-type="bibr">49</xref>].</p><p>Additive manufacturing is a manufacturing process that builds objects layer by layer using computer-aided design (CAD) data. The technique has made significant inroads in the field of medicine and healthcare due to its unique capabilities and advantages. Key medical applications include custom implants and prosthetics, tissue and organ bioprinting, dental restorations, and personal medications etc. [<xref rid="B50-polymers-16-01667" ref-type="bibr">50</xref>,<xref rid="B51-polymers-16-01667" ref-type="bibr">51</xref>].</p><p>In contrast, PLGA is a biodegradable and biocompatible copolymer derived from the combination of two naturally occurring compounds, lactic acid and glycolic acid. PLGA is a widely used synthetic polymer in the field of biomedicine, pharmaceuticals, and tissue engineering due to its favorable properties such as biodegradability, biocompatibility, and tunable degradation rate [<xref rid="B52-polymers-16-01667" ref-type="bibr">52</xref>]. Electrospinning is a nanofiber fabrication technique that utilizes an electrostatic field to produce ultrafine fibers, in the range of tens to hundreds of nanometers, from polymer solutions or melts. This ultrafine scale is valuable in distinct applications, such as tissue engineering, filtration, and drug delivery, where controlling material properties at the nanoscale is crucial [<xref rid="B53-polymers-16-01667" ref-type="bibr">53</xref>,<xref rid="B54-polymers-16-01667" ref-type="bibr">54</xref>].</p><p>Extensively investigated for tissue engineering applications, electrospun PLGA fibers possess a distinctive micro-/nanofibrous morphology that closely mimics the extracellular matrix. Spun nanofibers exhibit high porosity, a significant aspect ratio, and robust strength, facilitating improved tissue proliferation. These attributes endow nanofibers with considerable applications for drug delivery and tissue engineering. A hydrophilic surface promotes cell adhesion and proliferation, crucial for tissue engineering applications. It also aids in controlled drug release by facilitating the absorption of water, allowing for sustained release over time. Mukherjee and colleagues [<xref rid="B55-polymers-16-01667" ref-type="bibr">55</xref>] suggested that nanofibrous meshes offer a unique surface structure capable of retaining therapeutic cells for an extended period of up to six weeks, promoting significant infiltration by anti-inflammatory macrophages from the host. Achieving effective cell attachment to the scaffold is critical for success. Nevertheless, a challenge persists; the adoption of highly hydrophobic scaffold materials may lead to suboptimal cell colonization. Incorporating pharmaceuticals into the nanofibers enhances their hydrophilic properties [<xref rid="B56-polymers-16-01667" ref-type="bibr">56</xref>], thereby fostering the growth of connective tissues for FPOP repair. PLGA nanofibers with incorporated drugs also exhibited exceptional flexibility and extensibility, making them well-suited for functions in pelvic floor repair. This characteristic facilitates tissue contraction in the recovery process. Furthermore, nanofibers produced through electrospinning and embedded with pharmaceuticals offer customizable and sustained drug release. Localized pharmaceutical transport ensures elevated and sustained drug levels in the designated tissue, minimizing systemic doses and associated risks of hypoglycemia.</p><p>In general, the release of drugs from a resorbable device containing pharmaceuticals follows three separate phases: burst release, diffusion-governed discharge, and degradation-governed elution [<xref rid="B57-polymers-16-01667" ref-type="bibr">57</xref>]. In the electrospinning procedure, a significant portion of charged drugs is encased within the polymeric matrix volume. However, a few drugs may be situated on the surface of the fibrous membrane, resulting in burst release. Following the initial peak release, the drug liberation is regulated through diffusion and polymer degradation. Minor peak drug discharges could then be observed for the incorporated pharmaceuticals; thereafter, the release profiles diminished progressively. The empirical findings substantiated that the produced nanofibers release effective ketorolac and estrone (above the minimum therapeutic concentration) for a period of 30 days. This is advantageous for pain control [<xref rid="B58-polymers-16-01667" ref-type="bibr">58</xref>] and can aid in alleviating vaginal symptoms of menopause, including vaginal dryness, burning, and itching [<xref rid="B59-polymers-16-01667" ref-type="bibr">59</xref>]. However, the nanofibrous membrane only sustainably discharges efficient metronidazole and bleomycin (above the minimum inhibitory concentration) for 9 and 3 days in vitro, respectively. Fortunately, the electrospun nanofibers released elevated drug levels for over 28 days in vivo, offering advantages as an effective scaffold for FPOP repair.</p><p>Kao et al. [<xref rid="B60-polymers-16-01667" ref-type="bibr">60</xref>] developed degradable anti-adhesive PLGA nanofibrous membranes incorporating vancomycin/ceftazidime, ketorolac, and human epidermal growth factor (hEGF). Their findings revealed that these membranes released high concentrations of vancomycin/ceftazidime, ketorolac, and hEGF in vitro for over 30, 24, and 27 days, respectively. Moreover, they demonstrated that the anti-adhesive nanofibers provided postoperative pain relief and infection control, while also promoting the healing of surgical wounds in a rat model. Tugzu-Demiroz and colleagues [<xref rid="B61-polymers-16-01667" ref-type="bibr">61</xref>] employed electrospinning to create metronidazole-loaded nanofibers and proposed them as a potent pharmaceutical delivery system for addressing bacterial vaginosis. In a related investigation, Srithep et al. [<xref rid="B62-polymers-16-01667" ref-type="bibr">62</xref>] formulated electrospun nanofiber mats incorporating metronidazole for addressing periodontal disease. They observed an entrapment efficiency of metronidazole within the range of 82% to 99%, featuring an initial release of no less than 30% of the drug, followed by sustained release spanning 7 days. To prolong the duration of sustained drug release from PLGA mats, potential strategies encompass higher pharmaceutical loading, an augmented polymer/drug ratio, the utilization of greater molecular-weight polymers, and/or the establishment of a strongly oriented nanofibrous structure. On the other hand, bleomycin is a medication used in the treatment of cancer, specifically as a chemotherapeutic agent [<xref rid="B63-polymers-16-01667" ref-type="bibr">63</xref>]. It is part of a class of drugs known as antitumor antibiotics, which also induce tissue fibrosis. However, bleomycin is associated with potentially severe side effects, including pulmonary toxicity and skin reactions. Utilizing resorbable nanofibers, we can achieve localized delivery of medication to the pelvic floor. This approach enables the delivery of high drug concentrations directly to the target tissue, promoting tissue fibrosis and strengthening the pelvic floor. Meanwhile, the systemic drug level in blood is low, avoiding the risk of potential lung toxicity.</p><p>There were constraints within this initial study. We utilized a rat model to assess the effectiveness of drug-loaded scaffolds. The animal model employed was a healthy model rather than a diseased model. In addition, the applicability of the current discoveries to individuals with pelvic organ prolapse is uncertain and necessitates additional investigation. Considering the mechanical support that the scaffold should provide, some long-term mechanical tests and live ultrasounds could be included to comprehensively evaluate the efficacy of the scaffold. Long-term degradation tests and cellular assessments of printed mesh and spun nanofibers may be needed to confirm the non-toxicity of the scaffolds. Further experiments are also required to validate the potential of bleomycin in promoting tissue fibrosis for pelvic floor repair. These areas become the focus of forthcoming research endeavors.</p></sec><sec sec-type="conclusions" id="sec5-polymers-16-01667"><title>5. Conclusions</title><p>In this investigation, degradable nHA-filled PCL mesh/drug-eluting PLGA nanofibrous scaffolds were developed to replicate the microstructure of the natural extracellular matrix found in various connective tissues, created through additive manufacturing and electrospinning techniques. The proposed scaffold holds promise in mitigating potential complications associated with the treatment of FPOP while offering significant enhancements to current therapeutic approaches. One potential complication that the novel material may alleviate is the risk of mesh-related complications, commonly observed with traditional PP meshes, such as erosion, infection, and chronic pain. By utilizing a resorbable PCL mesh reinforced with nHA, augmented by drug-eluting PLGA nanofibers, the proposed scaffold offers improved biocompatibility and reduced risk of adverse reactions. Additionally, the enhanced mechanical properties of the scaffold provide robust support to pelvic organs, minimizing the likelihood of recurrence and prolapse. Furthermore, the controlled release of therapeutic agents from the PLGA nanofibers offers targeted treatment, addressing inflammation and promoting tissue regeneration, thereby fostering better long-term outcomes for individuals grappling with FPOP.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: Y.-P.C. and T.-S.L.; funding acquisition S.-J.L.; investigation: Y.-P.C., Y.-H.C. and Y.-H.K.; writing: S.-J.L.; supervision S.-J.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The entire procedures involving animals acquired approval from the Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital (IACUC: CGMH2018121905).</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data used to support the findings of this study are included within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-polymers-16-01667"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bureau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>K.V.</given-names></name></person-group><article-title>Pelvic organ prolapse: A primer for urologists</article-title><source>Can. Urol. Assoc. J.</source><year>2017</year><volume>11</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.5489/cuaj.4634</pub-id><pub-id pub-id-type="pmid">28616110</pub-id><pub-id pub-id-type="pmcid">PMC5461143</pub-id></element-citation></ref><ref id="B2-polymers-16-01667"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aub&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>L.M.</given-names></name></person-group><article-title>Current trends and future perspectives in pelvic reconstructive surgery</article-title><source>Women&#8217;s Health</source><year>2018</year><volume>14</volume><fpage>1745506518776498</fpage><pub-id pub-id-type="doi">10.1177/1745506518776498</pub-id><pub-id pub-id-type="pmid">29772955</pub-id><pub-id pub-id-type="pmcid">PMC5960843</pub-id></element-citation></ref><ref id="B3-polymers-16-01667"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#228;llenbach</surname><given-names>P.</given-names></name></person-group><article-title>To mesh or not to mesh: A review of pelvic organ reconstructive surgery</article-title><source>Int. J. Women&#8217;s Health</source><year>2015</year><volume>7</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.2147/IJWH.S71236</pub-id><pub-id pub-id-type="pmid">25848324</pub-id><pub-id pub-id-type="pmcid">PMC4386830</pub-id></element-citation></ref><ref id="B4-polymers-16-01667"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganj</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ibeanu</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Bedestani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Chesson</surname><given-names>R.R.</given-names></name></person-group><article-title>Complications of transvaginal monofilament polypropylene mesh in pelvic organ prolapse repair</article-title><source>Int. Urogynecol. J.</source><year>2009</year><volume>20</volume><fpage>919</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1007/s00192-009-0879-9</pub-id><pub-id pub-id-type="pmid">19582383</pub-id></element-citation></ref><ref id="B5-polymers-16-01667"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Pue</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.Y.</given-names></name></person-group><article-title>Long term outcomes of transobturator synthetic nonabsorbable anterior mesh versus anterior colporraphy in symptomatic advanced pelvic organ prolapse surgery</article-title><source>Int. Urogynecol. J.</source><year>2014</year><volume>25</volume><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s00192-013-2200-1</pub-id><pub-id pub-id-type="pmid">23942979</pub-id></element-citation></ref><ref id="B6-polymers-16-01667"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Pue</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>E.F.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.Y.</given-names></name></person-group><article-title>Clinical outcomes of mesh extrusion: Presentation, timing and management</article-title><source>Aust. N. Z. J. Obstet. Gynaecol.</source><year>2015</year><volume>55</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1111/ajo.12340</pub-id><pub-id pub-id-type="pmid">26044791</pub-id></element-citation></ref><ref id="B7-polymers-16-01667"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name></person-group><article-title>Fabrication of drug-eluting polycaprolac-tone/poly(lactic-co-glycolic acid) prolapse mats ssing solution-extrusion 3D printing and coaxial electrospinning techniques</article-title><source>Polymers</source><year>2021</year><volume>13</volume><elocation-id>2295</elocation-id><pub-id pub-id-type="doi">10.3390/polym13142295</pub-id><pub-id pub-id-type="pmid">34301052</pub-id><pub-id pub-id-type="pmcid">PMC8309226</pub-id></element-citation></ref><ref id="B8-polymers-16-01667"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rynkevic</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vange</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gallego</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Wach</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Deprest</surname><given-names>J.</given-names></name></person-group><article-title>In vitro simulation of in vivo degradation and cyclic loading of novel degradable electrospun meshes for prolapse repair</article-title><source>Polym. Test.</source><year>2019</year><volume>78</volume><fpage>105957</fpage><pub-id pub-id-type="doi">10.1016/j.polymertesting.2019.105957</pub-id></element-citation></ref><ref id="B9-polymers-16-01667"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shek</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>H.P.</given-names></name></person-group><article-title>Assessment of pelvic organ prolapse: A review</article-title><source>Ultrasound Obstet. Gynecol.</source><year>2016</year><volume>48</volume><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1002/uog.15881</pub-id><pub-id pub-id-type="pmid">26865209</pub-id></element-citation></ref><ref id="B10-polymers-16-01667"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#248;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Angl&#232;s-Acedo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Batra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Br&#230;kken</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Jorge</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dumoulin</surname><given-names>C.</given-names></name></person-group><article-title>Strenuous physical activity, exercise, and pelvic organ prolapse: A narrative scoping review</article-title><source>Int. Urogynecol. J.</source><year>2023</year><volume>34</volume><fpage>1153</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1007/s00192-023-05450-3</pub-id><pub-id pub-id-type="pmid">36692525</pub-id><pub-id pub-id-type="pmcid">PMC10238337</pub-id></element-citation></ref><ref id="B11-polymers-16-01667"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>T.-S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.-H.</given-names></name></person-group><article-title>The efficacy and complications of using transvaginal mesh to treat pelvic organ prolapse in Taiwan: A 10-year review</article-title><source>Taiwan. J. Obstet. Gynecol.</source><year>2021</year><volume>60</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.tjog.2021.01.031</pub-id><pub-id pub-id-type="pmid">33678316</pub-id></element-citation></ref><ref id="B12-polymers-16-01667"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Robles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mancinelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mancuso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Garcia-Romero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Casettari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Larraneta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lamprou</surname><given-names>D.A.</given-names></name></person-group><article-title>3D printing of drug-loaded thermoplastic polyurethane meshes: A potential material for soft tissue reinforcement in vaginal surgery</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12010063</pub-id><pub-id pub-id-type="pmid">31941047</pub-id><pub-id pub-id-type="pmcid">PMC7023419</pub-id></element-citation></ref><ref id="B13-polymers-16-01667"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name></person-group><article-title>Fabrication of drug-eluting nano-hydroxylapatite filled polycaprolactone nanocomposites using solution-extrusion 3D printing technique</article-title><source>Polymers</source><year>2021</year><volume>13</volume><elocation-id>318</elocation-id><pub-id pub-id-type="doi">10.3390/polym13030318</pub-id><pub-id pub-id-type="pmid">33498261</pub-id><pub-id pub-id-type="pmcid">PMC7863968</pub-id></element-citation></ref><ref id="B14-polymers-16-01667"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodruff</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hutmacher</surname><given-names>D.W.</given-names></name></person-group><article-title>The return of a forgotten polymer&#8212;Polycaprolactone in the 21st century</article-title><source>Prog. Polym. Sci.</source><year>2010</year><volume>35</volume><fpage>1217</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1016/j.progpolymsci.2010.04.002</pub-id></element-citation></ref><ref id="B15-polymers-16-01667"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Andriyana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Afifi</surname><given-names>A.M.</given-names></name></person-group><article-title>A review on fabrication of nanofibers via electrospinning and their applications</article-title><source>SN Appl. Sci.</source><year>2019</year><volume>1</volume><fpage>1248</fpage><pub-id pub-id-type="doi">10.1007/s42452-019-1288-4</pub-id></element-citation></ref><ref id="B16-polymers-16-01667"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>I.K.</given-names></name></person-group><article-title>A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology</article-title><source>Arab. J. Chem.</source><year>2018</year><volume>11</volume><fpage>1165</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2015.11.015</pub-id></element-citation></ref><ref id="B17-polymers-16-01667"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Gundloori</surname><given-names>R.V.N.</given-names></name></person-group><article-title>A review on electrospun nanofibers for multiple biomedical applications</article-title><source>Polym. Adv. Technol.</source><year>2023</year><volume>34</volume><fpage>44</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1002/pat.5896</pub-id></element-citation></ref><ref id="B18-polymers-16-01667"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmowafy</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Tiboni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>M.E.</given-names></name></person-group><article-title>Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles</article-title><source>J. Pharm. Investig.</source><year>2019</year><volume>49</volume><fpage>347</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1007/s40005-019-00439-x</pub-id></element-citation></ref><ref id="B19-polymers-16-01667"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leitsch</surname><given-names>D.</given-names></name></person-group><article-title>A review on metronidazole: An old warhorse in antimicrobial chemotherapy</article-title><source>Parasitology</source><year>2019</year><volume>146</volume><fpage>1167</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1017/S0031182017002025</pub-id><pub-id pub-id-type="pmid">29166971</pub-id></element-citation></ref><ref id="B20-polymers-16-01667"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robbie</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>R.L.</given-names></name></person-group><article-title>Metronidazole use in obstetrics and gynecology: A review</article-title><source>Am. J. Obstet. Gynecol.</source><year>1983</year><volume>145</volume><fpage>865</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1016/0002-9378(83)90693-2</pub-id><pub-id pub-id-type="pmid">6340508</pub-id></element-citation></ref><ref id="B21-polymers-16-01667"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzuillo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Calligaris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Amoroso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barbi</surname><given-names>E.</given-names></name></person-group><article-title>Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children</article-title><source>Acta Paediatr.</source><year>2018</year><volume>107</volume><fpage>560</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1111/apa.14189</pub-id><pub-id pub-id-type="pmid">29247538</pub-id></element-citation></ref><ref id="B22-polymers-16-01667"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avouac</surname><given-names>J.</given-names></name></person-group><article-title>Mouse model of experimental dermal fibrosis: The bleomycin-induced dermal fibrosis</article-title><source>Methods Mol. Biol.</source><year>2014</year><volume>1142</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">24706279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-0404-4_11</pub-id></element-citation></ref><ref id="B23-polymers-16-01667"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#322;yszczuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kania</surname><given-names>G.</given-names></name><name name-style="western"><surname>Distler</surname><given-names>O.</given-names></name></person-group><article-title>Experimental mouse model of bleomycin-induced skin fibrosis</article-title><source>Curr. Protoc. Immunol.</source><year>2019</year><volume>126</volume><fpage>e88</fpage><pub-id pub-id-type="doi">10.1002/cpim.88</pub-id><pub-id pub-id-type="pmid">31483105</pub-id></element-citation></ref><ref id="B24-polymers-16-01667"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Carlo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tommaselli</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gargano</surname><given-names>V.</given-names></name><name name-style="western"><surname>Savoia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nappi</surname><given-names>C.</given-names></name></person-group><article-title>Transdermal estradiol and oral or vaginal natural progesterone: Bleeding patterns</article-title><source>Climacteric</source><year>2010</year><volume>13</volume><fpage>442</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.3109/13697137.2010.490605</pub-id><pub-id pub-id-type="pmid">20575654</pub-id></element-citation></ref><ref id="B25-polymers-16-01667"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name></person-group><article-title>Novel additively manufactured tubular scaffold combined with electrospun biomolecules-embedded nanofibers promotes healing of ruptured tendon</article-title><source>Mater. Des.</source><year>2023</year><volume>230</volume><fpage>111953</fpage><pub-id pub-id-type="doi">10.1016/j.matdes.2023.111953</pub-id></element-citation></ref><ref id="B26-polymers-16-01667"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name></person-group><article-title>Development of novel hybrid 3D-printed degradable artificial joints incorporating electrospun pharmaceutical- and growth factor-loaded nanofibers for small joint reconstruction</article-title><source>Biomater. Adv.</source><year>2024</year><volume>159</volume><elocation-id>213821</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioadv.2024.213821</pub-id><pub-id pub-id-type="pmid">38428121</pub-id></element-citation></ref><ref id="B27-polymers-16-01667"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.-C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>K.-C.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>M.-J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Juang</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>I.-C.</given-names></name><etal/></person-group><article-title>Codelivery of sustainable antimicrobial agents and platelet-derived growth factor via biodegradable nanofibers for repair of diabetic infectious wounds</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>2688</fpage><lpage>2697</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00321</pub-id><pub-id pub-id-type="pmid">32902952</pub-id></element-citation></ref><ref id="B28-polymers-16-01667"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name></person-group><article-title>Anti-adhesive resorbable indomethacin/bupivacaine-eluting nanofibers for tendon rupture repair: In vitro and in vivo studies</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>16235</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242216235</pub-id><pub-id pub-id-type="pmid">38003425</pub-id><pub-id pub-id-type="pmcid">PMC10671766</pub-id></element-citation></ref><ref id="B29-polymers-16-01667"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name></person-group><article-title>Determination of electrospinning parameters&#8217; strength in poly(D,L)-lactide-co-glycolide micro/nanofibers diameter tailoring</article-title><source>J. Nanomater.</source><year>2019</year><volume>2019</volume><fpage>2626085</fpage><pub-id pub-id-type="doi">10.1155/2019/2626085</pub-id></element-citation></ref><ref id="B30-polymers-16-01667"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Feola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meyn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abramowitch</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Moalli</surname><given-names>P.A.</given-names></name></person-group><article-title>Tensile properties of commonly used prolapse meshes</article-title><source>Int. Urogynecol. J.</source><year>2009</year><volume>20</volume><fpage>847</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1007/s00192-008-0781-x</pub-id><pub-id pub-id-type="pmcid">PMC3028597</pub-id><pub-id pub-id-type="pmid">19495548</pub-id></element-citation></ref><ref id="B31-polymers-16-01667"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tashtoush</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>M.</given-names></name></person-group><article-title>Validation of a simple and rapid HPLC method for determination of metronidazole in dermatological formulations</article-title><source>Drug Dev. Ind. Pharm.</source><year>2008</year><volume>34</volume><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1080/03639040801928598</pub-id><pub-id pub-id-type="pmid">18618307</pub-id></element-citation></ref><ref id="B32-polymers-16-01667"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muralidharan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Parasuraman</surname><given-names>S.</given-names></name></person-group><article-title>Simple and sensitive method for the analysis of ketorolac in human plasma using high-performance liquid chromatography</article-title><source>J. Young Pharm.</source><year>2013</year><volume>5</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.jyp.2013.06.007</pub-id><pub-id pub-id-type="pmid">24396250</pub-id><pub-id pub-id-type="pmcid">PMC3812891</pub-id></element-citation></ref><ref id="B33-polymers-16-01667"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mabeta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dippenaar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shelver</surname><given-names>G.</given-names></name></person-group><article-title>A validated HPLC method for the simultaneous determination of bleomycin A2 and B2 in human plasma</article-title><source>Int. J. Pharm. Biomed. Res.</source><year>2012</year><volume>3</volume><fpage>191</fpage><lpage>194</lpage></element-citation></ref><ref id="B34-polymers-16-01667"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geisler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berntsen</surname><given-names>H.</given-names></name><name name-style="western"><surname>L&#248;nning</surname><given-names>P.E.</given-names></name></person-group><article-title>A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2000</year><volume>72</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/S0960-0760(00)00036-4</pub-id><pub-id pub-id-type="pmid">10822015</pub-id></element-citation></ref><ref id="B35-polymers-16-01667"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashtarinezhad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shirazi</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Vatanpour</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mohamazadehasl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Panahyab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakhjavani</surname><given-names>M.</given-names></name></person-group><article-title>FTIR-microspectroscopy detection of metronidazole teratogenic effects on mice fetus</article-title><source>Iran. J. Pharm. Res.</source><year>2014</year><volume>13</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">24711835</pub-id><pub-id pub-id-type="pmcid">PMC3977059</pub-id></element-citation></ref><ref id="B36-polymers-16-01667"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amul</surname><given-names>B.</given-names></name><name name-style="western"><surname>Muthu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sevvanthi</surname><given-names>S.</given-names></name></person-group><article-title>Molecular structure, spectroscopic (FT-IR, FT-Raman, NMR, UV-VIS), chemical reactivity and biological examinations of Ketorolac</article-title><source>J. Mol. Struct.</source><year>2020</year><volume>1210</volume><fpage>128040</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2020.128040</pub-id></element-citation></ref><ref id="B37-polymers-16-01667"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neese</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zaleski</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Zaleski</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>E.I.</given-names></name></person-group><article-title>Electronic structure of activated bleomycin:&#8201; Oxygen intermediates in heme versus non-heme iron</article-title><source>J. Am. Chem. Soc.</source><year>2000</year><volume>122</volume><fpage>11703</fpage><lpage>11724</lpage><pub-id pub-id-type="doi">10.1021/ja001812y</pub-id></element-citation></ref><ref id="B38-polymers-16-01667"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Separation and determination of estrogen in the water environment by high performance liquid chromatography-fourier transform infrared spectroscopy</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>32264</fpage><pub-id pub-id-type="doi">10.1038/srep32264</pub-id><pub-id pub-id-type="pmid">27577974</pub-id><pub-id pub-id-type="pmcid">PMC5006044</pub-id></element-citation></ref><ref id="B39-polymers-16-01667"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agafonova</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Moshchenskiy</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Tkachenko</surname><given-names>M.L.</given-names></name></person-group><article-title>DSC study and calculation of metronidazole and clarithromycin thermodynamic melting parameters for individual substances and for eutectic mixture</article-title><source>Thermochim. Acta</source><year>2014</year><volume>580</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.tca.2014.01.018</pub-id></element-citation></ref><ref id="B40-polymers-16-01667"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Trehan</surname><given-names>A.</given-names></name></person-group><article-title>Development, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres as a depot system for parenteral delivery</article-title><source>Drug Deliv.</source><year>2008</year><volume>15</volume><fpage>365</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1080/10717540500398092</pub-id><pub-id pub-id-type="pmid">18686080</pub-id></element-citation></ref><ref id="B41-polymers-16-01667"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>U.K.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.M.</given-names></name></person-group><article-title>Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells</article-title><source>Colloids Surf. B</source><year>2014</year><volume>118</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2014.03.036</pub-id><pub-id pub-id-type="pmid">24732397</pub-id></element-citation></ref><ref id="B42-polymers-16-01667"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.-Q.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.-K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.-J.</given-names></name></person-group><article-title>Estrogen promotes the growth of decidual stromal cells in human early pregnancy</article-title><source>Mol. Hum. Reprod.</source><year>2013</year><volume>19</volume><fpage>655</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1093/molehr/gat034</pub-id><pub-id pub-id-type="pmid">23649593</pub-id></element-citation></ref><ref id="B43-polymers-16-01667"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Antimicrobial susceptibility sesting of metronidazole and clindamycin against Gardnerella vaginalis in planktonic and biofilm formation</article-title><source>Can. J. Infect. Dis. Med. Microbiol.</source><year>2020</year><volume>2020</volume><elocation-id>1361825</elocation-id><pub-id pub-id-type="doi">10.1155/2020/1361825</pub-id><pub-id pub-id-type="pmid">32612729</pub-id><pub-id pub-id-type="pmcid">PMC7315270</pub-id></element-citation></ref><ref id="B44-polymers-16-01667"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hersh</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Dionne</surname><given-names>R.A.</given-names></name></person-group><source>17&#8212;Nonopioid Analgesics. Pharmacology and Therapeutics for Dentistry</source><edition>7th ed.</edition><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2017</year><fpage>25</fpage><lpage>275</lpage></element-citation></ref><ref id="B45-polymers-16-01667"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khair</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Patnaik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>S.</given-names></name></person-group><article-title>Effect of bleomycin on oral leukoplakia cell line&#8212;An in vitro study</article-title><source>Oral Surg. Oral Med. Oral Pathol. Oral Radiol.</source><year>2023</year><volume>135</volume><fpage>e41</fpage><pub-id pub-id-type="doi">10.1016/j.oooo.2022.09.024</pub-id></element-citation></ref><ref id="B46-polymers-16-01667"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genant</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Baylink</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Steiger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Herber</surname><given-names>M.</given-names></name></person-group><article-title>Effect of estrone sulfate on postmenopausal bone loss</article-title><source>Obstet. Gynecol.</source><year>1990</year><volume>76</volume><fpage>579</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/0020-7292(91)90313-T</pub-id><pub-id pub-id-type="pmid">2170884</pub-id></element-citation></ref><ref id="B47-polymers-16-01667"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dwivedi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nandana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>D.</given-names></name></person-group><article-title>Polycaprolactone as biomaterial for bone scaffolds: Review of literature</article-title><source>J. Oral Biol. Craniofacial Res.</source><year>2020</year><volume>10</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.jobcr.2019.10.003</pub-id><pub-id pub-id-type="pmid">31754598</pub-id><pub-id pub-id-type="pmcid">PMC6854079</pub-id></element-citation></ref><ref id="B48-polymers-16-01667"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name></person-group><article-title>In-vitro release of anti-proliferative paclitaxel from novel balloon-expandable polycaprolactone stents</article-title><source>Mater. Sci. Eng. C</source><year>2011</year><volume>31</volume><fpage>1129</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2011.04.011</pub-id></element-citation></ref><ref id="B49-polymers-16-01667"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.-C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name></person-group><article-title>Novel bioresorbable drug-eluting mesh scaffold for therapy of muscle injury</article-title><source>ACS Biomater. Sci. Eng.</source><year>2024</year><volume>10</volume><fpage>2595</fpage><lpage>2606</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.3c01669</pub-id><pub-id pub-id-type="pmid">38480510</pub-id></element-citation></ref><ref id="B50-polymers-16-01667"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghilan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiriac</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Nita</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Rusu</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Neamtu</surname><given-names>I.</given-names></name></person-group><article-title>Trends in 3D Printing Processes for Biomedical Field: Opportunities and Challenges</article-title><source>J. Polym. Environ.</source><year>2020</year><volume>28</volume><fpage>1345</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1007/s10924-020-01722-x</pub-id><pub-id pub-id-type="pmid">32435165</pub-id><pub-id pub-id-type="pmcid">PMC7224028</pub-id></element-citation></ref><ref id="B51-polymers-16-01667"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Kashani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imbalzano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K.T.Q.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D.</given-names></name></person-group><article-title>Additive manufacturing (3D printing): A review of materials, methods, applications and challenges</article-title><source>Compos. Part B Eng.</source><year>2018</year><volume>143</volume><fpage>172</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.compositesb.2018.02.012</pub-id></element-citation></ref><ref id="B52-polymers-16-01667"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hines</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>D.L.</given-names></name></person-group><article-title>Poly (lactic-co-glycolic acid) controlled release systems: Experimental and modeling insights</article-title><source>Crit. Rev. Ther. Drug Carr. Syst.</source><year>2013</year><volume>30</volume><fpage>257</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1615/CritRevTherDrugCarrierSyst.2013006475</pub-id><pub-id pub-id-type="pmid">23614648</pub-id><pub-id pub-id-type="pmcid">PMC3719420</pub-id></element-citation></ref><ref id="B53-polymers-16-01667"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name></person-group><article-title>Electrospinning and electrospun nanofibers: Methods, materials, and applications</article-title><source>Chem. Rev.</source><year>2019</year><volume>119</volume><fpage>5298</fpage><lpage>5415</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00593</pub-id><pub-id pub-id-type="pmid">30916938</pub-id><pub-id pub-id-type="pmcid">PMC6589095</pub-id></element-citation></ref><ref id="B54-polymers-16-01667"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chinnappan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramakrishna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>R.</given-names></name></person-group><article-title>A review on electrospun nanofibers based advanced applications: From health care to energy devices</article-title><source>Polymers</source><year>2021</year><volume>13</volume><elocation-id>3746</elocation-id><pub-id pub-id-type="doi">10.3390/polym13213746</pub-id><pub-id pub-id-type="pmid">34771302</pub-id><pub-id pub-id-type="pmcid">PMC8587893</pub-id></element-citation></ref><ref id="B55-polymers-16-01667"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Darzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosamilia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kadam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Werkmeister</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gargett</surname><given-names>C.E.</given-names></name></person-group><article-title>Blended nanostructured degradable mesh with endometrial mesenchymal stem cells promotes tissue integration and anti-inflammatory response in vivo for pelvic floor application</article-title><source>Biomacromolecules</source><year>2019</year><volume>20</volume><fpage>454</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.8b01661</pub-id><pub-id pub-id-type="pmid">30512928</pub-id></element-citation></ref><ref id="B56-polymers-16-01667"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Caetano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ambler</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Blaker</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Frade</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diver</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bartolo</surname><given-names>P.</given-names></name></person-group><article-title>Enhancing the hydrophilicity and cell attachment of 3D printed PCL/graphene scaffolds for bone tissue engineering</article-title><source>Materials</source><year>2016</year><volume>9</volume><elocation-id>992</elocation-id><pub-id pub-id-type="doi">10.3390/ma9120992</pub-id><pub-id pub-id-type="pmid">28774112</pub-id><pub-id pub-id-type="pmcid">PMC5456956</pub-id></element-citation></ref><ref id="B57-polymers-16-01667"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hrib</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sirc</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hobzova</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hampejsova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bosakova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Munzarova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>J.</given-names></name></person-group><article-title>Nanofibers for drug delivery&#8212;Incorporation and release of model molecules, influence of molecular weight and polymer structure</article-title><source>Beilstein J. Nanotechnol.</source><year>2015</year><volume>6</volume><fpage>1939</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.3762/bjnano.6.198</pub-id><pub-id pub-id-type="pmid">26665065</pub-id><pub-id pub-id-type="pmcid">PMC4660903</pub-id></element-citation></ref><ref id="B58-polymers-16-01667"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forestell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sabbineni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharif</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eltorki</surname><given-names>M.</given-names></name></person-group><article-title>Comparative effectiveness of ketorolac dosing strategies for emergency department patients with acute pain</article-title><source>Ann. Emerg. Med.</source><year>2023</year><volume>82</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2023.04.011</pub-id><pub-id pub-id-type="pmid">37178102</pub-id></element-citation></ref><ref id="B59-polymers-16-01667"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersion</surname><given-names>T.L.G.</given-names></name><name name-style="western"><surname>Stehle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Davidsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoglund</surname><given-names>P.</given-names></name></person-group><article-title>Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems: Menorest and Climara</article-title><source>Maturitas</source><year>2000</year><volume>35</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/S0378-5122(00)00129-8</pub-id><pub-id pub-id-type="pmid">10936741</pub-id></element-citation></ref><ref id="B60-polymers-16-01667"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>He</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name></person-group><article-title>Lidocaine/ketorolac loaded biodegradable nanofibrous anti-adhesive membranes that offer sustained pain relief for surgical wounds</article-title><source>Int. J. Nanomed.</source><year>2017</year><volume>12</volume><fpage>5893</fpage><lpage>5901</lpage><pub-id pub-id-type="doi">10.2147/IJN.S140825</pub-id><pub-id pub-id-type="pmid">28860755</pub-id><pub-id pub-id-type="pmcid">PMC5566388</pub-id></element-citation></ref><ref id="B61-polymers-16-01667"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu&#287;cu-Demir&#246;z</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tort</surname><given-names>S.</given-names></name><name name-style="western"><surname>Acart&#252;rk</surname><given-names>F.</given-names></name></person-group><article-title>Electrospun metronidazole-loaded nanofibers for vaginal drug delivery</article-title><source>Drug Dev. Ind. Pharm.</source><year>2020</year><volume>46</volume><fpage>1015</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1080/03639045.2020.1767125</pub-id><pub-id pub-id-type="pmid">32393132</pub-id></element-citation></ref><ref id="B62-polymers-16-01667"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srithep</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akkaprasa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pholharn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Patrojanasophon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ngawhirunpat</surname><given-names>T.</given-names></name></person-group><article-title>Metronidazole-loaded polylactide stereocomplex electrospun nanofiber mats for treatment of periodontal disease</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2021</year><volume>64</volume><fpage>102582</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2021.102582</pub-id></element-citation></ref><ref id="B63-polymers-16-01667"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>D&#8217;Ortenzio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name></person-group><article-title>Targeted delivery of bleomycin: A comprehensive anticancer review</article-title><source>Curr. Cancer Drug Targets</source><year>2016</year><volume>16</volume><fpage>509</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.2174/1568009616666151130213910</pub-id><pub-id pub-id-type="pmid">26632436</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="polymers-16-01667-f001" orientation="portrait"><label>Figure 1</label><caption><p>Photos of (<bold>A</bold>) the lab-made solution-extrusion additive manufacturing device, (<bold>B</bold>) additively manufactured mesh, and (<bold>C</bold>) schematically, the drug-eluting scaffold is composed of nHA filled PCL mesh and bi-layered drug-eluting nanofibers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g001.jpg"/></fig><fig position="float" id="polymers-16-01667-f002" orientation="portrait"><label>Figure 2</label><caption><p>PCL mesh implantation and retrieval. (<bold>A</bold>) Integration of nHA filled PCL meshes and drug-loaded PLGA nanofibers via sutures, (<bold>B</bold>) exposed peritoneal herniation, (<bold>C</bold>) placement of mesh/nanofibers on peritoneal defect, (<bold>D</bold>) retrieved mesh/nanofibers with peritoneum at 28 days post-implantation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g002.jpg"/></fig><fig position="float" id="polymers-16-01667-f003" orientation="portrait"><label>Figure 3</label><caption><p>Tensile properties of additively manufactured virgin polycaprolactone (PCL) meshes and nHA filled PCL meshes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g003.jpg"/></fig><fig position="float" id="polymers-16-01667-f004" orientation="portrait"><label>Figure 4</label><caption><p>Stress&#8211;strain curves of virgin poly (lactic-co-glycolic acid) (PLGA) nanofibers and drug-loaded PLGA nanofibers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g004.jpg"/></fig><fig position="float" id="polymers-16-01667-f005" orientation="portrait"><label>Figure 5</label><caption><p>Scanning electron microscopy (SEM) images and fiber diameter distribution of (<bold>A</bold>) polycaprolactone (PCL) mesh, (<bold>B</bold>) virgin poly(lactic-co-glycolic acid) (PLGA) nanofibers, (<bold>C</bold>) metronidazole/ketorolac/PLGA nanofibers, and (<bold>D</bold>) bleomycin/estrone/PLGA nanofibers. Spun virgin PLGA nanofibers (537.8 &#177; 333.4 nm) exhibited superior size distribution to those of metronidazole/ketorolac/PLGA nanofibers (165.5 &#177; 54.3 nm) and bleomycin/estrone/PLGA nanofibers (84.9 &#177; 33.6 nm).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g005.jpg"/></fig><fig position="float" id="polymers-16-01667-f006" orientation="portrait"><label>Figure 6</label><caption><p>Water contact angles of (<bold>A</bold>) virgin poly (lactic-co-glycolic acid) (PLGA) nanofibers, 118.2&#176;, (<bold>B</bold>) metronidazole and ketorolac loaded PLGA nanofibers, 78.0&#176;, (<bold>C</bold>) bleomycin and estrone embedded PLGA nanofibers, 54.3&#176;.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g006.jpg"/></fig><fig position="float" id="polymers-16-01667-f007" orientation="portrait"><label>Figure 7</label><caption><p>Fourier transform infrared spectroscopy (FTIR) spectra of metronidazole and ketorolac loaded PLGA nanofibers, and bleomycin and estrone embedded PLGA nanofibers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g007.jpg"/></fig><fig position="float" id="polymers-16-01667-f008" orientation="portrait"><label>Figure 8</label><caption><p>Fourier transform infrared spectroscopy (FTIR) spectra, (<bold>A</bold>) metronidazole and ketorolac loaded PLGA nanofibers, (<bold>B</bold>) bleomycin and estrone embedded PLGA nanofibers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g008.jpg"/></fig><fig position="float" id="polymers-16-01667-f009" orientation="portrait"><label>Figure 9</label><caption><p>HPLC chromatograms of the pharmaceuticals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g009.jpg"/></fig><fig position="float" id="polymers-16-01667-f010" orientation="portrait"><label>Figure 10</label><caption><p>In vitro (<bold>A</bold>) daily, (<bold>B</bold>) cumulative release of pharmaceuticals from the nanofibers. The minimum inhibitory concentrations (MICs) of metronidazole, ketorolac, and bleomycin were 8, 0.03, and 15 &#956;g/mL, respectively. Meanwhile, the minimum therapeutic concentration (MTC) of estrone was 1.36 pg/mL, which is too low to be shown in the upper figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g010.jpg"/></fig><fig position="float" id="polymers-16-01667-f011" orientation="portrait"><label>Figure 11</label><caption><p>In vivo release of (<bold>A</bold>) ketorolac, (<bold>B</bold>) bleomycin, (<bold>C</bold>) metronidazole, (<bold>D</bold>) estrone from the resorbable nanofibrous prolapse meshes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g011.jpg"/></fig><fig position="float" id="polymers-16-01667-f012" orientation="portrait"><label>Figure 12</label><caption><p>Hematoxylin and eosin staining of tissues. (D1 represents as day 1; D3 represents as day 3; D7 represents as day 7; D14 represents as day 14; D28 represents as day 28) (scale bar: 100 &#956;m).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g012.jpg"/></fig><fig position="float" id="polymers-16-01667-f013" orientation="portrait"><label>Figure 13</label><caption><p>Histological images (400&#215;) with Masson&#8217;s trichrome stain post-implantation. Red area: muscle fiber, blue area: collagen fiber. (D1 represents as day 1; D3 represents as day 3; D7 represents as day 7; D14 represents as day 14; D28 represents as day 28) (scale bar: 200 &#956;m).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="polymers-16-01667-g013.jpg"/></fig></floats-group></article></pmc-articleset>